LBM22
LBM22 is a CDC2-like kinase 2 (CLK2) inhibitor with the IC50 of 3.9 nM. LBM22 has antiproliferative activity and inhibits serine/arginine-rich (SR) protein phosphorylation. LBM22 down-regulates the expression of Wnt-related proteins and anti-apoptotic proteins and can be used for study of non-small cell lung cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; CDK; Wnt
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lbm22.html
Smiles
FC1(F)CN(CC2=CN=CC(C3=CC4=C(NN=C4C5=NC(C6=CC=CO6)=C(C7=CC=CO7)N5)C=C3)=C2)CC1
Molecular Formula
C28H22F2N6O2
Molecular Weight
512.51
References & Citations
[1]Hu T, et al. Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer. Eur J Med Chem. 2024 Oct 9;280:116952.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgG Immunoglobulin (IG266), CF488A conjugate, 0.1mg/mL
CD50 (ICAM-3) (186-2G9), CF594 conjugate, 0.1mg/mL
Fibronectin (HFN7.1), CF405S conjugate, 0.1mg/mL
EGFR (GFR1195 + 31G7), CF640R conjugate, 0.1mg/mL
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R), CF740 conjugate, 0.1mg/mL
